Ehlers-Danlos syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:27:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ehlers-Danlos syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Valsartan for Slowing Aortic Root Dilatation in Children and Young Adults with Marfan Syndrome and Related Conditions https://clinicaltrials.eu/trial/study-on-valsartan-for-slowing-aortic-root-dilatation-in-children-and-young-adults-with-marfan-syndrome-and-related-conditions/ Wed, 29 Apr 2026 14:22:27 +0000 https://clinicaltrials.eu/trial/study-on-valsartan-for-slowing-aortic-root-dilatation-in-children-and-young-adults-with-marfan-syndrome-and-related-conditions/ This clinical trial is focused on studying the effects of the medication valsartan in children and young adults who have certain genetic conditions that affect the heart’s main artery, known as the aorta. These conditions include Marfan syndrome and related diseases such as Loeys-Dietz syndrome, Vascular type of Ehlers-Danlos syndrome, and others that can cause the aorta to become enlarged or develop aneurysms. The purpose of the study is to evaluate whether valsartan can help slow down the enlargement of the aorta in these patients.

Participants in the study will receive either valsartan or a placebo, which is a substance with no active medication. Valsartan is a medication commonly used to treat high blood pressure and heart failure. It is being tested here to see if it can help manage the size of the aorta in people with these genetic conditions. The study will last for a period of up to 36 months, during which participants will take the medication orally in the form of tablets.

Throughout the study, the size of the aorta will be monitored using medical imaging techniques like transthoracic echocardiography, which is a type of ultrasound that looks at the heart and aorta. The goal is to see if there is a difference in the rate of aortic enlargement between those taking valsartan and those taking the placebo. This research aims to provide valuable information on whether valsartan can be an effective treatment option for managing aortic enlargement in these genetic conditions.

]]>